Skip to content
10-K

Annual Report

Alterola Biotech, Inc.

0001663577-24-000211

← back to feed
Filed
Jul 18, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jun 28, 2024 1.47B sh
Operating Cash Flow FY 2024 · Mar 31, 2024 −$1.45M
Operating Cash Flow restated FY 2024 · Mar 31, 2023 −$1.31M
Stockholders Equity FY 2024 · Mar 31, 2024 −$1.33M
Stockholders Equity restated FY 2024 · Mar 31, 2023 $9.76M
Current Liabilities FY 2024 · Mar 31, 2024 $1.33M
Current Liabilities restated FY 2024 · Mar 31, 2023 $2.13M
Total Liabilities FY 2024 · Mar 31, 2024 $1.33M
Total Liabilities restated FY 2024 · Mar 31, 2023 $2.29M
Current Assets FY 2024 · Mar 31, 2024 $3.66K
Current Assets restated FY 2024 · Mar 31, 2023 $46.32K
Total Assets FY 2024 · Mar 31, 2024 $3.66K
Total Assets restated FY 2024 · Mar 31, 2023 $12.05M
Sga Expense FY 2024 · Mar 31, 2024 $252K
Sga Expense restated FY 2024 · Mar 31, 2023 $67.72K
Rd Expense FY 2024 · Mar 31, 2024 $28.77K
Rd Expense restated FY 2024 · Mar 31, 2023 $181.81K
Net Income FY 2024 · Mar 31, 2024 −$2.37M
Net Income restated FY 2024 · Mar 31, 2023 −$2.07M
Operating Income FY 2024 · Mar 31, 2024 −$2.11M
Operating Income restated FY 2024 · Mar 31, 2023 −$2.03M